US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alcobra

10.22

+0.0000

Volume:- -

Turnover:- -

Market Cap:281.69M

PE:-11.48

High:10.22

Open:10.22

Low:10.22

Close:10.22

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Alcobra

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.alcobra-pharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADHD/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADHD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","market":"US","secType":"STK","nameCN":"Alcobra","latestPrice":10.22,"timestamp":1510952400000,"preClose":10.22,"halted":4,"volume":0,"delay":0,"floatShares":8881019,"shares":27563000,"eps":-0.89,"marketStatus":"Delisted","change":0,"latestTime":"11-17 16:00:00 EST","open":10.22,"high":10.22,"low":10.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","floatShares":8881019,"roa":"--","roe":"--","lyrEps":0,"shares":27563000,"dividePrice":0,"high":10.22,"amplitude":0,"preClose":10.22,"low":10.22,"week52Low":5.8113,"pbRate":"5.96","week52High":18.0414,"institutionHeld":0,"latestPrice":10.22,"eps":-0.89,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.89,"open":10.22},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.alcobra-pharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0606},{"period":"6month","weight":-0.0566},{"period":"1year","weight":0.0849},{"period":"ytd","weight":-0.0371}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.","exchange":"NASDAQ","name":"Alcobra","nameEN":"Alcobra"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADHD\",params:#limit:5,,,undefined,":[{"date":"2017-11-16","symbol":"ADHD","newSymbol":"ARCT","type":"symbolChange","dateTimestamp":1510808400000},{"date":"2017-11-15","symbol":"ADHD","type":"split","dateTimestamp":1510722000000,"forFactor":7,"toFactor":1},{"market":"US","date":"2017-11-09","symbol":"ADHD","fiscalQuarterEnding":"2017/09","expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2017-08-11","symbol":"ADHD","fiscalQuarterEnding":"2017/06","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1502424000000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2017-05-30","symbol":"ADHD","fiscalQuarterEnding":"2017/03","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1496116800000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADHD\",market:\"US\",delay:false,,,undefined,":{}}}